Website
N/ATelephone
64.3.479.5800
Address
87 St. David Street Centre for Innovation Dunedin, Otago 9016
Description
Pacific Edge Ltd. engages in the provision of discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. It operates in the Commercial and Research segments. The Commercial segment involves the sales, marketing, laboratory, and support to run the commercial businesses worldwide. The Research segment engages in the research and development of diagnostic and prognostic products for human cancer. The company was founded on February 27, 2001 and is headquartered in Dunedin, New Zealand.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.07 - 0.13
Trade Value (12mth)
AU$664.00
1 week
-1.22%
1 month
3.85%
YTD
-26.36%
1 year
-13.83%
All time high
1.61
EPS 3 yr Growth
77.00%
EBITDA Margin
-132.20%
Operating Cashflow
-$24m
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
-56.80
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
811m
HALO Sector
Healthcare
Next Company Report Date
29-May-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.13
Date | Announcements |
---|---|
05 September 24 |
Pacific Edge Chairman Delays Retirement
×
Pacific Edge Chairman Delays Retirement |
15 August 24 |
Notice of Annual Shareholder Meeting and Proxy Form 2024
×
Notice of Annual Shareholder Meeting and Proxy Form 2024 |
29 July 24 |
Novitas Confirms Medicare Coverage Review Extension
×
Novitas Confirms Medicare Coverage Review Extension |
26 July 24 |
Medicare Coverage Determination Still Under Review
×
Medicare Coverage Determination Still Under Review |
16 July 24 |
Director Nomination Closing Date
×
Director Nomination Closing Date |
11 July 24 |
Notification regarding unquoted securities - PEB
×
Notification regarding unquoted securities - PEB |
11 July 24 |
Application for quotation of securities - PEB
×
Application for quotation of securities - PEB |
10 July 24 |
Quarterly Update - Cxbladder Test Volumes Steady in Q1 25
×
Quarterly Update - Cxbladder Test Volumes Steady in Q1 25 |
09 July 24 |
Notification of cessation of securities - PEB
×
Notification of cessation of securities - PEB |
27 June 24 |
Annual Report 2024
×
Annual Report 2024 |
21 May 24 |
Cash Burn Slows Coverage Catalysts in Focus
×
Cash Burn Slows Coverage Catalysts in Focus |
01 May 24 |
Pacific Edge Full Year Result to be Announced 21 May 2024
×
Pacific Edge Full Year Result to be Announced 21 May 2024 |
01 May 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
01 May 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
30 April 24 |
Clinical Utility of Cxbladder to Headline at AUA 2024
×
Clinical Utility of Cxbladder to Headline at AUA 2024 |
09 April 24 |
Quarterly Update - Cxbladder Test Volumes Steady in Q4 24
×
Quarterly Update - Cxbladder Test Volumes Steady in Q4 24 |
14 March 24 |
Pacific Edge Directors Give Notice of Retirement
×
Pacific Edge Directors Give Notice of Retirement |
22 January 24 |
Quarterly Update - Test Volumes Fall Following Restructure
×
Quarterly Update - Test Volumes Fall Following Restructure |
22 January 24 |
Cxbladder Test Volumes Correction
×
Cxbladder Test Volumes Correction |
15 December 23 |
Application for quotation of securities - PEB
×
Application for quotation of securities - PEB |
05 December 23 |
Change in substantial holding
×
Change in substantial holding |
23 November 23 |
Financial Results for the Half Year to 30 September 2023
×
Financial Results for the Half Year to 30 September 2023 |
15 November 23 |
Kaiser Permanente EMR Integration goes live
×
Kaiser Permanente EMR Integration goes live |
25 October 23 |
NZX - Capital Change Notice
×
NZX - Capital Change Notice |
25 October 23 |
NZX - D&O Disclosures - P Meintjes & G Gibson - 25 Oct 23
×
NZX - D&O Disclosures - P Meintjes & G Gibson - 25 Oct 23 |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.